NYSEAMERICAN:ATNM

Actinium Pharmaceuticals News Headlines

$7.50
+0.36 (+5.04 %)
(As of 04/21/2021 02:16 PM ET)
Add
Compare
Today's Range
$7.15
Now: $7.50
$7.50
50-Day Range
$7.80
MA: $10.35
$11.82
52-Week Range
$4.71
Now: $7.50
$19.47
Volume2,467 shs
Average Volume389,070 shs
Market Capitalization$144.35 million
P/E RatioN/A
Dividend YieldN/A
Beta1.23

Headlines

Actinium Pharmaceuticals (NYSEAMERICAN ATNM) News Headlines Today

SourceHeadline
William Blair Weighs in on Actinium Pharmaceuticals, Inc.s Q1 2021 Earnings (NYSEAMERICAN:ATNM)William Blair Weighs in on Actinium Pharmaceuticals, Inc.'s Q1 2021 Earnings (NYSEAMERICAN:ATNM)
americanbankingnews.com - April 19 at 1:28 AM
Glenmark Pharma’s API arm files papers with Sebi to unlock value via IPOGlenmark Pharma’s API arm files papers with Sebi to unlock value via IPO
msn.com - April 17 at 7:55 AM
Global Healthcare API Market (2020 to 2025) - Featuring Apple, General Electric and Cerner Among Others - ResearchAndMarkets.comGlobal Healthcare API Market (2020 to 2025) - Featuring Apple, General Electric and Cerner Among Others - ResearchAndMarkets.com
ca.finance.yahoo.com - April 13 at 8:23 AM
Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Forecasted to Post Q2 2021 Earnings of ($0.62) Per ShareActinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Forecasted to Post Q2 2021 Earnings of ($0.62) Per Share
americanbankingnews.com - April 9 at 8:18 AM
Novel Cancer Therapy Phase 3 Trial Expects To Be Completed ShortlyNovel Cancer Therapy Phase 3 Trial Expects To Be Completed Shortly
markets.businessinsider.com - April 6 at 11:36 AM
Actinium Pharmaceuticals (NYSEMKT:ATNM) Is In A Good Position To Deliver On Growth PlansActinium Pharmaceuticals (NYSEMKT:ATNM) Is In A Good Position To Deliver On Growth Plans
finance.yahoo.com - April 5 at 7:09 AM
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Releases  Earnings Results, Meets EstimatesActinium Pharmaceuticals (NYSEAMERICAN:ATNM) Releases Earnings Results, Meets Estimates
americanbankingnews.com - April 2 at 8:06 AM
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) PT Lowered to $57.00 at HC WainwrightActinium Pharmaceuticals (NYSEAMERICAN:ATNM) PT Lowered to $57.00 at HC Wainwright
americanbankingnews.com - April 1 at 10:18 AM
Actinium to Participate in the Cell & Gene Meeting on the MediterraneanActinium to Participate in the Cell & Gene Meeting on the Mediterranean
finance.yahoo.com - March 31 at 6:48 PM
Actinium initiates patient enrollment in Iomab-ACT trial prior to CD19 CAR t-cell therapyActinium initiates patient enrollment in Iomab-ACT trial prior to CD19 CAR t-cell therapy
seekingalpha.com - March 26 at 12:36 AM
Actinium Announces Completion of Enrollment of Second Dose Cohort in Actimab-A Venetoclax Combination Trial for Patients with R/R AMLActinium Announces Completion of Enrollment of Second Dose Cohort in Actimab-A Venetoclax Combination Trial for Patients with R/R AML
finance.yahoo.com - March 25 at 9:34 AM
Actinium Announces Initiation of Patient Enrollment in Iomab-ACT Trial for Targeted Conditioning Prior to CD19 CAR T-Cell TherapyActinium Announces Initiation of Patient Enrollment in Iomab-ACT Trial for Targeted Conditioning Prior to CD19 CAR T-Cell Therapy
finance.yahoo.com - March 24 at 7:58 AM
Actinium to Highlight Expansion of Targeted Conditioning Portfolio at AACR with Next-Generation Actinium-225-Based CD45 Targeting ARCActinium to Highlight Expansion of Targeted Conditioning Portfolio at AACR with Next-Generation Actinium-225-Based CD45 Targeting ARC
finance.yahoo.com - March 11 at 7:37 AM
Actinium Announces Appointment of Mark Kubik, MBA as Chief Business OfficerActinium Announces Appointment of Mark Kubik, MBA as Chief Business Officer
finance.yahoo.com - March 3 at 7:43 AM
Actinium Announces Participation in H.C. Wainwright Global Life Sciences ConferenceActinium Announces Participation in H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - March 2 at 9:11 AM
Actinium Showcases Targeted Conditioning Program with 2 Oral Presentations Highlighting Iomab-B and Pivotal Phase 3 SIERRA Trial at 2021 Transplantation & Cellular Therapy Annual MeetingActinium Showcases Targeted Conditioning Program with 2 Oral Presentations Highlighting Iomab-B and Pivotal Phase 3 SIERRA Trial at 2021 Transplantation & Cellular Therapy Annual Meeting
finance.yahoo.com - February 11 at 8:05 AM
Actinium Announces Participation in BIO CEO & Investor Digital ConferenceActinium Announces Participation in BIO CEO & Investor Digital Conference
finance.yahoo.com - February 10 at 7:37 AM
Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor ConferenceActinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference
finance.yahoo.com - January 20 at 8:15 AM
Actinium Pharma Announces Research Collaboration With Astellas - Quick FactsActinium Pharma Announces Research Collaboration With Astellas - Quick Facts
markets.businessinsider.com - January 13 at 8:01 AM
Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted RadiotherapiesActinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies
finance.yahoo.com - January 13 at 7:23 AM
Actinium Says DMC Recommends Phase 3 SIERRA Trial Continue To Full Enrolment Of 150 PatientsActinium Says DMC Recommends Phase 3 SIERRA Trial Continue To Full Enrolment Of 150 Patients
nasdaq.com - December 29 at 9:45 AM
Actinium Announces Successful Pre-Planned Ad Hoc Interim Analysis of Phase 3 SIERRA trialActinium Announces Successful Pre-Planned Ad Hoc Interim Analysis of Phase 3 SIERRA trial
finance.yahoo.com - December 29 at 8:55 AM
ATNM.A - Actinium Pharmaceuticals Inc Profile | ReutersATNM.A - Actinium Pharmaceuticals Inc Profile | Reuters
reuters.com - December 26 at 12:53 AM
Actinium Pharmaceuticals (ATNM) Gains As Market Dips: What You Should KnowActinium Pharmaceuticals (ATNM) Gains As Market Dips: What You Should Know
finance.yahoo.com - December 9 at 8:29 PM
Actinium Highlights Presence at Targeted Radiopharmaceuticals SummitActinium Highlights Presence at Targeted Radiopharmaceuticals Summit
finance.yahoo.com - December 9 at 8:50 AM
Benzinga Global Small Cap Conference Day 1 Recap: Sorrento, Arcimoto And Much MoreBenzinga Global Small Cap Conference Day 1 Recap: Sorrento, Arcimoto And Much More
benzinga.com - December 8 at 8:26 PM
Actinium Reveals 67 Percent Overall Response Rate In Actimab-A Venetoclax Combination TrialActinium Reveals 67 Percent Overall Response Rate In Actimab-A Venetoclax Combination Trial
nasdaq.com - December 8 at 9:52 AM
Actinium Reports 67 Percent Overall Response Rate in First Cohort in Actimab-A Venetoclax Combination Trial in Relapsed and Refractory AML at ASHActinium Reports 67 Percent Overall Response Rate in First Cohort in Actimab-A Venetoclax Combination Trial in Relapsed and Refractory AML at ASH
finance.yahoo.com - December 8 at 9:16 AM
Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 75% of Total Patient Enrollment at the 62nd American Society of Hematology Annual MeetingActinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 75% of Total Patient Enrollment at the 62nd American Society of Hematology Annual Meeting
finance.yahoo.com - December 7 at 8:48 AM
Actinium Presents Interim Data from Actimab-A CLAG-M Phase 1 Combination Trial at the 62nd American Society of Hematology Annual MeetingActinium Presents Interim Data from Actimab-A CLAG-M Phase 1 Combination Trial at the 62nd American Society of Hematology Annual Meeting
finance.yahoo.com - December 7 at 7:43 AM
Actinium Pharmaceuticals: Our Bullish View Is Intact On Promising Early Stage ResultsActinium Pharmaceuticals: Our Bullish View Is Intact On Promising Early Stage Results
seekingalpha.com - December 5 at 9:07 PM
Is Actinium Pharmaceuticals (ATNM) A Good Stock To Buy Now?Is Actinium Pharmaceuticals (ATNM) A Good Stock To Buy Now?
finance.yahoo.com - December 2 at 11:02 PM
Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical DevelopmentActinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
finance.yahoo.com - December 1 at 7:32 AM
Actinium Pharma Highlights Intellectual Property Portfolio For ApamistamabActinium Pharma Highlights Intellectual Property Portfolio For Apamistamab
nasdaq.com - November 23 at 8:11 AM
Actinium Highlights Foundational Patents Covering the Composition of Apamistamab Antibody and Iomab-B Antibody Radiation Conjugate for Targeted Conditioning Until 2037 and Recent EU Patent ActivityActinium Highlights Foundational Patents Covering the Composition of Apamistamab Antibody and Iomab-B Antibody Radiation Conjugate for Targeted Conditioning Until 2037 and Recent EU Patent Activity
finance.yahoo.com - November 23 at 8:11 AM
Actinium Strengthens Leadership Team with Appointment of Dr. Avinash Desai as Executive Vice President of Clinical Development, Operations and Medical AffairsActinium Strengthens Leadership Team with Appointment of Dr. Avinash Desai as Executive Vice President of Clinical Development, Operations and Medical Affairs
finance.yahoo.com - November 19 at 7:41 AM
ATNM Nov 2020 2.500 call(CONTRAATNM Nov 2020 2.500 call(CONTRA
finance.yahoo.com - November 19 at 1:08 AM
Actinium to Participate in the Alliance Global Partners Virtual Healthcare SymposiumActinium to Participate in the Alliance Global Partners' Virtual Healthcare Symposium
finance.yahoo.com - November 16 at 7:20 AM
Actinium to Host KOL Call on November 11th Featuring Actimab-A AML Combination TrialsActinium to Host KOL Call on November 11th Featuring Actimab-A AML Combination Trials
finance.yahoo.com - November 11 at 8:08 AM
Actinium Announces Actimab-A Venetoclax First-in-Human Data Accepted for Poster Presentation at the 62nd American Society of Hematology Annual MeetingActinium Announces Actimab-A Venetoclax First-in-Human Data Accepted for Poster Presentation at the 62nd American Society of Hematology Annual Meeting
finance.yahoo.com - November 4 at 1:15 PM
Actinium Announces Two Oral Presentations Featuring Data and Findings from the Phase 3 SIERRA Trial of Iomab-B at the 62nd American Society of Hematology Annual MeetingActinium Announces Two Oral Presentations Featuring Data and Findings from the Phase 3 SIERRA Trial of Iomab-B at the 62nd American Society of Hematology Annual Meeting
finance.yahoo.com - November 4 at 1:15 PM
100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 Combination Trial in Patients with Relapsed or Refractory AML100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 Combination Trial in Patients with Relapsed or Refractory AML
finance.yahoo.com - November 4 at 1:15 PM
Actinium Sees Multiple Milestones In Q4 From ARC Pipeline Incl Phase 3 Data From SIERRA TrialActinium Sees Multiple Milestones In Q4 From ARC Pipeline Incl Phase 3 Data From SIERRA Trial
markets.businessinsider.com - October 28 at 9:56 AM
Actinium Pharmaceuticals, Inc. Provides Corporate Update and Year-End 2020 OutlookActinium Pharmaceuticals, Inc. Provides Corporate Update and Year-End 2020 Outlook
finance.yahoo.com - October 28 at 7:27 AM
Actinium Pharma cheers National Institutes of Health grant to study novel Iomab-ACTActinium Pharma cheers National Institutes of Health grant to study novel Iomab-ACT
seekingalpha.com - October 21 at 9:08 AM
Actinium Pharmaceuticals, Inc. Awarded Grant by National Institutes of Health to Study Novel Iomab-ACT Targeted Conditioning with a CD19 CAR T-Cell TherapyActinium Pharmaceuticals, Inc. Awarded Grant by National Institutes of Health to Study Novel Iomab-ACT Targeted Conditioning with a CD19 CAR T-Cell Therapy
finance.yahoo.com - October 21 at 7:40 AM
Actinium Pharmaceuticals, Inc. Expands R&D Capabilities with New Research Facility to Enhance Development of Next Generation Antibody Radiation Conjugates Leveraging Its Proprietary AWE PlatformActinium Pharmaceuticals, Inc. Expands R&D Capabilities with New Research Facility to Enhance Development of Next Generation Antibody Radiation Conjugates Leveraging Its Proprietary AWE Platform
finance.yahoo.com - October 14 at 10:10 PM
Actinium Pharmaceuticals expands R&D capabilities with new research facility in New York CityActinium Pharmaceuticals expands R&D capabilities with new research facility in New York City
seekingalpha.com - October 14 at 12:09 PM
Actinium concludes dosing cohort in Phase 1 Actimab-A/venetoclax combination trialActinium concludes dosing cohort in Phase 1 Actimab-A/venetoclax combination trial
seekingalpha.com - September 23 at 9:37 AM
Actinium Pharmaceuticals Successfully Completes First Dosing Cohort in the Phase 1 Study of Actimab-A and Venetoclax Combination Therapy in Relapsed/Refractory AML PatientsActinium Pharmaceuticals Successfully Completes First Dosing Cohort in the Phase 1 Study of Actimab-A and Venetoclax Combination Therapy in Relapsed/Refractory AML Patients
finance.yahoo.com - September 23 at 9:37 AM
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.